Linde PLC Overview
Industry: Specialty Chemicals
Sector: Basic Materials
Linde plc operates as an industrial gas company in North and South America, Europe, the Middle East, Africa, and the Asia Pacific. It offers atmospheric gases, including oxygen, nitrogen, argon, and rare gases; and process gases, such as carbon dioxide, helium, hydrogen, electronic gases, specialty gases, and acetylene. The company also designs and constructs turnkey process plants for third-party customers, as well as for the gas businesses in various locations, such as air separation, hydrogen, synthesis, olefin, and natural gas plants. It serves a range of industries, including healthcare, chemicals and energy, manufacturing, metals and mining, food and beverage, and electronics. The company was founded in 1879 and is based in Woking, the United Kingdom. Linde plc operates as an industrial gas company in North and South America, Europe, the Middle East, Africa, and the Asia Pacific. It offers atmospheric gases, including oxygen, nitrogen, argon, and rare gases; and process gases, such as carbon dioxide, helium, hydrogen, electronic gases, specialty Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Linde PLC into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $9,289M (reported); EPS was $4.15 (+9% YoY).
What changed
- Revenue reported to $9,289M; EPS +9% YoY to $4.15.
- Capital return update: free cash flow $833M.
Guidance / outlook
the company expects adjusted diluted earnings per share to be in the range of $17.70 to $17.90, up 8% to 9% when assuming favorable currency of 1% versus prior year.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Cue Biopharma CEO Lin sells shares worth $1.6 million
Headline from Investing.com: Cue Biopharma CEO Lin sells shares worth $1.6 million.
Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000
Headline from Investing.com: Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000.
Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000
Headline from Investing.com Nigeria: Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000.
Linde Plc - LIN - Stock Price & News
Headline from The Motley Fool: Linde Plc - LIN - Stock Price & News.
Thermal Spray Service Competitive Landscape Led by Oerlikon Metco, TOCALO, StandardAero, Linde Surface Technologies and Chromalloy
Headline from Yahoo Finance: Thermal Spray Service Competitive Landscape Led by Oerlikon Metco, TOCALO, StandardAero, Linde Surface Technologies and Chromalloy.
Europe Liquid Hydrogen Market Report 2026–2035: Evaluating $13.1 Billion Forecast, Cryogenic Distribution, and Strategies of Linde, Air Liquide, Chart Industries, and Air Products
Headline from Yahoo Finance: Europe Liquid Hydrogen Market Report 2026–2035: Evaluating $13.1 Billion Forecast, Cryogenic Distribution, and Strategies of Linde, Air Liquide, Chart Industries, and Air Products.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.